The effect of individualized NUTritional counseling on muscle mass and treatment outcome in patients with metastatic COLOrectal cancer undergoing chemotherapy: a randomized controlled trial protocol

BMC Cancer

Marian AE de van der Schueren³  Henk MW Verheul²  Johannes Berkhof¹  Jacqueline AE Langius⁴  Susanne Blauwhoff-Buskermolen²  Anne van der Werf² 

[1]Department of Epidemiology en Biostatistics, VU University, Amsterdam, The Netherlands

[2]Department of Medical Oncology, Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands

[3]Faculty of Health and Social Studies, Department of Nutrition, Sports and Health, HAN University of Applied Sciences, Nijmegen, The Netherlands

[4]Faculty of Health, Nutrition and Sport, The Hague University of Applied Sciences, The Hague, The Netherlands

关键词: Survival;    Treatment toxicity;    Quality of life;    Nutritional counseling;    Muscle mass;    Malnutrition;    Colorectal cancer;   

Others  :  1136244
DOI  :  10.1186/s12885-015-1092-5

 received in 2014-10-23, accepted in 2015-02-20,  发布年份 2015

【 摘 要 】

Background

A low muscle mass is prevalent in patients with metastatic colorectal cancer (mCRC) and has been associated with poor treatment outcome. Chemotherapeutic treatment has an additional unfavorable effect on muscle mass. Sufficient protein intake and physical activity are known to induce muscle protein anabolism in healthy individuals, however it is unclear whether optimal nutrition is effective to preserve muscle mass in patients with mCRC during first-line chemotherapy as well. We hypothesize that individual nutritional counseling by a trained dietitian during first-line chemotherapy is effective in preserving muscle mass and may improve clinical outcomes in patients with mCRC.

Methods/Design

In this multi-center single-blind randomized controlled trial, patients with mCRC scheduled for first-line combination chemotherapy consisting of oxaliplatin and fluoropyrimidine, with or without bevacizumab (n = 110), will be randomized to receive either individualized nutritional counseling by a trained dietitian to achieve a sufficient dietary intake and an adequate physical activity level, or usual care. Outcome measures will be assessed at baseline and after two and four months of treatment. The primary endpoint will be the change in skeletal muscle area (measured by CT-scan) at the first treatment evaluation. Secondary endpoints will be quality of life, physical functioning, treatment toxicity, treatment intensity and survival. Statistical analyses include one-sided t-tests for the primary endpoint and mixed models and the Kaplan-Meier method for secondary endpoints.

Discussion

This randomized controlled trial will provide evidence whether individualized nutritional counseling during chemotherapy is effective in preventing loss of muscle mass in patients with mCRC.

Trial registration

ClinicalTrials.gov NCT01998152 webcite; Netherlands Trial Register NTR4223 webcite.

【 授权许可】

   
2015 van der Werf et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]GLOBOCAN 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2014 [http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx]
• [2]Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014, 64:104-17.
• [3]Peeters M, Siena S, Tabernero J, Douillard J, Koukakis R, Terwey J, et al.: Survival outcomes in the PRIME study for patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), by baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) [abstract]. J Clin Oncol 2014, 32:5 s. suppl; abstr 3557^
• [4]Bazarbashi S, Aljubran AH, Al Zahrani A, Edesa W, Nabil-Ahmed M, Shoukri M: Early tumor shrinkage versus early response as a predictor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with triplet chemotherapy regimens (TCR) [abstract]. Journal of Clinical Oncology 2014, 2014 (suppl; abstr e14580).
• [5]Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, et al.: A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G) [abstract]. J Clin Oncol 2014, 32:5 s. suppl; abstr 3534
• [6]Attar A, Malka D, Sabate JM, Bonnetain F, Lecomte T, Aparicio T, et al.: Malnutrition is high and underestimated during chemotherapy in gastrointestinal cancer: an AGEO prospective cross-sectional multicenter study. Nutr Cancer. 2012, 64:535-42.
• [7]Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Birdsell L, et al.: The association of nutritional assessment criteria with health-related quality of life in patients with advanced colorectal carcinoma. Eur J Cancer Care (Engl ). 2012, 21:505-16.
• [8]Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr 2013, 32:65-72.
• [9]Andreyev HJ, Norman AR, Oates J, Cunningham D: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998, 34:503-9.
• [10]Kern KA, Norton JA: Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988, 12:286-98.
• [11]Steinbach S, Hummel T, Bohner C, Berktold S, Hundt W, Kriner M, et al.: Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol. 2009, 27:1899-905.
• [12]Courneya KS, Friedenreich CM: Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med. 1997, 3:215-26.
• [13]Bernhardson BM, Tishelman C, Rutqvist LE: Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer. 2008, 16:275-83.
• [14]English KL, Paddon-Jones D: Protecting muscle mass and function in older adults during bed rest. Curr Opin Clin Nutr Metab Care. 2010, 13:34-9.
• [15]Barret M, Malka D, Aparicio T, Dalban C, Locher C, Sabate JM, et al.: Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. Oncology. 2011, 81:395-402.
• [16]Lucia A, Earnest C, Perez M: Cancer-related fatigue: can exercise physiology assist oncologists? Lancet Oncol. 2003, 4:616-25.
• [17]Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al.: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008, 9:629-35.
• [18]Marin Caro MM, Laviano A, Pichard C: Nutritional intervention and quality of life in adult oncology patients. Clin Nutr. 2007, 26:289-301.
• [19]Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al.: Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009, 15:2920-6.
• [20]Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E, Taieb J: Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer. Nutr Cancer 2014, 66(4):583-9.
• [21]Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009, 15:6973-9.
• [22]van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN: Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012, 99:550-7.
• [23]Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al.: Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011, 62:265-79.
• [24]Antoun S, Borget I, Lanoy E: Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care. 2013, 7:383-9.
• [25]McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009, 12:223-6.
• [26]Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al.: Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013, 31:1539-47.
• [27]Paddon-Jones D, Rasmussen BB: Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care. 2009, 12:86-90.
• [28]Wall BT, Morton JP, van Loon LJ: Strategies to maintain skeletal muscle mass in the injured athlete: Nutritional considerations and exercise mimetics. Eur J Sport Sci 2015, 15(1):53-62.
• [29]Baldwin C, Spiro A, McGough C, Norman AR, Gillbanks A, Thomas K, et al.: Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. J Hum Nutr Diet. 2011, 24:431-40.
• [30]Hasenberg T, Essenbreis M, Herold A, Post S, Shang E: Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomized clinical trial. Colorectal Dis. 2010, 12:e190-9.
• [31]Spiro A, Baldwin C, Patterson A, Thomas J, Andreyev HJ: The views and practice of oncologists towards nutritional support in patients receiving chemotherapy. Br J Cancer. 2006, 95:431-4.
• [32]Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, et al.: ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr. 2006, 25:245-59.
• [33]Nitenberg G, Raynard B: Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol. 2000, 34:137-68.
• [34]Dutch Institute for Healthcare Improvement CBO. Guideline Perioperative Nutrition. 2007.
• [35]Roza AM, Shizgal HM: The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. Am J Clin Nutr. 1984, 40:168-82.
• [36]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40:373-83.
• [37]Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008, 33:997-1006.
• [38]Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al.: Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 2004, 97:2333-8.
• [39]Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R: Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 1998, 85:115-22.
• [40]Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85:365-76.
• [41]Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A: The EORTC QLO-C30 Scoring Manual, 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer; 2001. 2014. European Organisation for Research and Treatment of Cancer, Brussels; 2001.
• [42]Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA: Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer. 2013, 21:3261-70.
• [43]Bohannon RW: Quantitative testing of muscle strength: Issues and practical options for the geriatric population. Top Geriatr Rehabil. 2002, 18:1-17.
• [44]Common Terminology Criteria for Adverse Events v4.0 (CTCAE) [http://www.eortc.be/services/doc/ctc/]
• [45]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47.
• [46]Tremblay A, Sevigny J, Leblanc C, Bouchard C: The Reproducibility of A 3-Day Dietary Record. Nutr Res. 1983, 3:819-30.
• [47]Slootmaker SM, Chin APM, Schuit AJ, van MW , Koppes LL: Concurrent validity of the PAM accelerometer relative to the MTI Actigraph using oxygen consumption as a reference. Scand J Med Sci Sports 2009, 19:36-43.
• [48]Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG, Evans WJ: Strength conditioning in older men: skeletal muscle hypertrophy and improved function. J Appl Physiol (1985) 1988, 64:1038-44.